Regulatory Analysis

FDA regulatory intelligence, warning letter breakdowns, and actionable analysis for brands across all FDA-regulated categories.

Weekly Roundup5 min read

Weekly FDA Roundup: salt substitutes cleared for cheddar, bread, and 137 other standardized foods, and Dreyer's warned over recurring Listeria, October 10–16, 2026

A final rule lets 139 standardized foods swap salt for substitutes like potassium chloride. Plus Dreyer's Listeria warning letter and two contract firms that bent microbiology data.

Read article →
Weekly FDA Roundup: salt substitutes cleared for cheddar, bread, and 137 other standardized foods, and Dreyer's warned over recurring Listeria, October 10–16, 2026
Amazon and Walmart FDA warning letters: herpes remedies their warehouses shipped
Warning Letter Analysis7 min

Amazon and Walmart FDA warning letters: herpes remedies their warehouses shipped

FDA bought herpes remedies on Amazon and Walmart.com, then warned both platforms and eight sellers. Amazon's 10th letter since 2022 shows what the fulfillment theory means for sellers.

Read more →
Weekly FDA Roundup: Amazon and Walmart warned over herpes remedies shipped from their warehouses, and FDA drafts a traceability reprieve for mid-size restaurants, October 3–9, 2026
Weekly Roundup5 min

Weekly FDA Roundup: Amazon and Walmart warned over herpes remedies shipped from their warehouses, and FDA drafts a traceability reprieve for mid-size restaurants, October 3–9, 2026

FDA bought herpes remedies on Amazon and Walmart.com, then warned both platforms and eight sellers. Plus a traceability reprieve for mid-size restaurants and one bad broccoli seed lot.

Read more →
Jalapeño Salmonella recall: how 53,760 bulk cases became 49 Class I entries
Regulatory Trends7 min

Jalapeño Salmonella recall: how 53,760 bulk cases became 49 Class I entries

Jalapeños traced to one Sinaloa grower sickened 488 people and led to 49 Class I recall entries from eight firms. What the cascade shows about traceability, FSMA 204 and FSVP.

Read more →
Weekly FDA Roundup: a "sterile" horse wound product is tied to at least 20 deaths, and FDA plans to replace its vape review rule, September 26–October 2, 2026
Weekly Roundup6 min

Weekly FDA Roundup: a "sterile" horse wound product is tied to at least 20 deaths, and FDA plans to replace its vape review rule, September 26–October 2, 2026

Fungus-contaminated HYCOAT is tied to nearly 100 horse joint infections and at least 20 deaths. Plus FDA's plan to rewrite the PMTA rule and 21 warning letters in one day.

Read more →
FDA's Empower Pharmacy warning letter: why vitamin-added GLP-1s were still "essentially copies"
Warning Letter Analysis5 min

FDA's Empower Pharmacy warning letter: why vitamin-added GLP-1s were still "essentially copies"

FDA says Empower Pharmacy's tirzepatide-niacinamide and semaglutide-B12 vials are essentially copies, citing order volume and menu-picked prescriber statements. What to change now.

Read more →
Weekly FDA Roundup: FDA calls Empower Pharmacy's GLP-1 vitamin blends "essentially copies," and an Impella controller recall follows three deaths, September 19–25, 2026
Weekly Roundup6 min

Weekly FDA Roundup: FDA calls Empower Pharmacy's GLP-1 vitamin blends "essentially copies," and an Impella controller recall follows three deaths, September 19–25, 2026

FDA says Empower Pharmacy's tirzepatide-niacinamide and semaglutide-B12 vials copy approved drugs. Plus an Impella controller recall, oleander sold as tejocote, and 7 FSVP letters.

Read more →
Weekly FDA Roundup: the seed supplier behind the alfalfa sprout outbreak recalls 43,799 pounds, and Bausch & Lomb gets a sterility warning letter, September 12–18, 2026
Weekly Roundup6 min

Weekly FDA Roundup: the seed supplier behind the alfalfa sprout outbreak recalls 43,799 pounds, and Bausch & Lomb gets a sterility warning letter, September 12–18, 2026

Two weeks after FDA said it had not responded, the seed supplier in the alfalfa sprout outbreak recalled 43,799 lbs. Plus Bausch & Lomb's warning letter and a Medtronic Class I recall.

Read more →
Huons lidocaine recall: 12 kit notices, 7 kit makers, and a two-month lag
Regulatory Trends7 min

Huons lidocaine recall: 12 kit notices, 7 kit makers, and a two-month lag

Recalled Huons lidocaine, bupivacaine and saline ampules sat inside kits from seven makers, including BD and B. Braun. FDA's recall notices trailed customer letters by about two months.

Read more →
Weekly FDA Roundup: BMC reports a quiet 2024 firmware fix as a Class I recall, and FDA drops PABA from sunscreen, September 5–11, 2026
Weekly Roundup6 min

Weekly FDA Roundup: BMC reports a quiet 2024 firmware fix as a Class I recall, and FDA drops PABA from sunscreen, September 5–11, 2026

BMC reported a 2024 firmware rework of 20,160 sleep therapy devices 19 months later, and up to 196 may lack the fix. Plus PABA leaves sunscreen and a broccoli sprout outbreak.

Read more →
Weekly FDA Roundup: five "research use only" peptide sellers get warning letters, and a spinal cord lead is tied to 1,081 serious injuries, August 29–September 4, 2026
Weekly Roundup6 min

Weekly FDA Roundup: five "research use only" peptide sellers get warning letters, and a spinal cord lead is tied to 1,081 serious injuries, August 29–September 4, 2026

FDA warned five online sellers that a "research use only" label doesn't make injectable semaglutide or retatrutide legal. Plus a Class I spinal cord lead recall and Fresenius's leaking bags.

Read more →
FDA's generative AI medical device paper: what its risk grid means for chatbot makers before October 19
Regulatory Trends6 min

FDA's generative AI medical device paper: what its risk grid means for chatbot makers before October 19

FDA's discussion paper on generative AI medical devices floats a two-axis risk grid and asks whether a "talk to your doctor" line lowers risk at all. Comments close October 19.

Read more →
Weekly FDA Roundup: 13 Class I entries trace back to one jalapeño distributor, and sprouts are tied to 55 illnesses, August 22–28, 2026
Weekly Roundup6 min

Weekly FDA Roundup: 13 Class I entries trace back to one jalapeño distributor, and sprouts are tied to 55 illnesses, August 22–28, 2026

FDA classified the jalapeño Salmonella outbreak recalls as Class I, starting with 53,760 cases at the source. Plus sprouts tied to 55 illnesses and Boston Scientific's ENROUTE recall.

Read more →
Moringa Salmonella recalls reach 15 since November, and the newest ones start at the bulk supplier
Regulatory Trends7 min

Moringa Salmonella recalls reach 15 since November, and the newest ones start at the bulk supplier

Moringa Salmonella recalls reached 15 events at 14 companies by late August. The newest began with bulk powder that was already inside other brands' products. What to ask your supplier.

Read more →
Weekly FDA Roundup: FDA sketches how it might regulate generative AI devices, 11 warning letters land in a day, and the Huons kit recalls hit their busiest week, August 15–21, 2026
Weekly Roundup5 min

Weekly FDA Roundup: FDA sketches how it might regulate generative AI devices, 11 warning letters land in a day, and the Huons kit recalls hit their busiest week, August 15–21, 2026

FDA asked 26 questions about regulating generative AI medical devices, posted 11 warning letters in one day, and logged three more kit actions tied to recalled Huons drug components.

Read more →
Mandatory GRAS Notification: What FDA's Proposed Rule Would Require of Ingredient Suppliers and Brands
Regulatory Trends7 min

Mandatory GRAS Notification: What FDA's Proposed Rule Would Require of Ingredient Suppliers and Brands

FDA's proposed rule would end self-affirmed GRAS. How the seven exceptions and the one-year window for existing ingredients work, and what to ask your suppliers before comments close December 9.

Read more →
Weekly FDA Roundup: FDA moves to make GRAS notices mandatory, one dairy's Listeria recall becomes 22 Class I entries, and jalapeño recalls spread, August 8–14, 2026
Weekly Roundup6 min

Weekly FDA Roundup: FDA moves to make GRAS notices mandatory, one dairy's Listeria recall becomes 22 Class I entries, and jalapeño recalls spread, August 8–14, 2026

FDA proposed making GRAS notification mandatory, classified 22 Listeria recall entries tied to one Maryland cheesemaker as Class I, and watched jalapeño Salmonella recalls reach 26 states.

Read more →
Red Dye 3 Ban: FDA Lifted the Stay, and the January 15, 2027 Deadline Never Moved
Regulatory Trends7 min

Red Dye 3 Ban: FDA Lifted the Stay, and the January 15, 2027 Deadline Never Moved

FDA overruled Micro-Tracers' objections and lifted the stay on its Red No. 3 repeal. Food and supplement makers have until January 15, 2027; ingested drugs until January 18, 2028.

Read more →
Weekly FDA Roundup: Red No. 3's January 2027 deadline is back on, and Salmonella returns to Food to Live's green powders, August 1–7, 2026
Weekly Roundup6 min

Weekly FDA Roundup: Red No. 3's January 2027 deadline is back on, and Salmonella returns to Food to Live's green powders, August 1–7, 2026

FDA lifts the stay on its Red No. 3 ban, confirming the January 15, 2027 food deadline. Plus Food to Live's green powders, DEG testing failures, and a morphine syringe mix-up.

Read more →
Weekly FDA Roundup: BD's intraosseous needle recall follows four deaths, and FSVP warning letters hit a 2026 high, July 25–31, 2026
Weekly Roundup5 min

Weekly FDA Roundup: BD's intraosseous needle recall follows four deaths, and FSVP warning letters hit a 2026 high, July 25–31, 2026

BD recalls intraosseous needle sets after 45 serious injuries and 4 deaths, two more moringa Salmonella recalls, FY2027 user fees, and five FSVP warning letters in one day.

Read more →
Weekly FDA Roundup: a 16-flavor ice pop recall, a food-dye cleanup, and 15 warning letters, July 18–24, 2026
Weekly Roundup6 min

Weekly FDA Roundup: a 16-flavor ice pop recall, a food-dye cleanup, and 15 warning letters, July 18–24, 2026

FDA's highest-risk recall of the week hit a box of paletas, while the agency revoked one petroleum food dye, moved against another, and pulled 1.5 million dozen eggs.

Read more →
Weekly FDA Roundup: Taylor Farms pulls all its Mexican iceberg lettuce, a recalled anesthetic keeps surfacing in surgical kits, and 13 warning letters land in a day, July 11–17, 2026
Weekly Roundup5 min

Weekly FDA Roundup: Taylor Farms pulls all its Mexican iceberg lettuce, a recalled anesthetic keeps surfacing in surgical kits, and 13 warning letters land in a day, July 11–17, 2026

A Cyclospora outbreak forced Taylor Farms to recall every head of Central Mexico iceberg across 27 states, while a recalled Huons anesthetic pulled two more surgical kit lines off the market.

Read more →
Two Class I Infant Formula Recalls in Five Weeks — and Neither One Was Cronobacter
Regulatory Trends5 min

Two Class I Infant Formula Recalls in Five Weeks — and Neither One Was Cronobacter

FDA classified two powdered infant formula recalls as Class I this summer — one for cereulide toxin, one for Clostridium botulinum covering all 377,610 cans. Neither was Cronobacter. Both organisms are spore-formers, which is a different control problem, and the Class I classification lagged the firms' own announcements by three to five weeks.

Read more →
Weekly FDA Roundup: botulism in infant formula, a ketamine warning-letter sweep, and a growing convenience-kit thread, July 4–10, 2026
Weekly Roundup6 min

Weekly FDA Roundup: botulism in infant formula, a ketamine warning-letter sweep, and a growing convenience-kit thread, July 4–10, 2026

FDA logged 44 actions this week, led by a Class I recall of Nara Organics infant formula tied to four confirmed infant botulism cases, plus 15 warning letters to online ketamine sellers.

Read more →
Revlon Got a Drug CGMP Warning Letter Without an Inspection. Here Is How That Works.
Regulatory Trends5 min

Revlon Got a Drug CGMP Warning Letter Without an Inspection. Here Is How That Works.

Thirteen of the 64 CGMP warning letters FDA published between May and July 2026 involved no inspection at all. FDA requested records under section 704(a)(4), read them, and issued the adulteration finding from the paperwork. Revlon's Oxford facility is on the list. Here is what it means if you make anything with an OTC active ingredient.

Read more →
Weekly FDA Roundup: seven million insulin pods recalled, a wave of Salmonella food recalls, and ten warning letters, June 27–July 3, 2026
Weekly Roundup5 min

Weekly FDA Roundup: seven million insulin pods recalled, a wave of Salmonella food recalls, and ten warning letters, June 27–July 3, 2026

FDA's most serious actions this week were four Class I device recalls, led by roughly 7 million Insulet Omnipod insulin pods, alongside a cluster of Class I food recalls and ten warning letters.

Read more →
FDA Has Sent Amazon Nine Warning Letters Since 2022. The Newest One Names Fulfillment by Amazon.
Warning Letter Analysis5 min

FDA Has Sent Amazon Nine Warning Letters Since 2022. The Newest One Names Fulfillment by Amazon.

FDA has issued nine warning letters to Amazon.com since August 2022, every one alleging the same violation: unapproved new drugs introduced into interstate commerce. The June 2026 letter changes the theory — it ties the violation to Fulfillment by Amazon. Here is what that means for third-party sellers.

Read more →
Weekly FDA Roundup: Amazon gets a warning letter, three Class I food recalls, and a foreign tobacco crackdown, June 20–26, 2026
Weekly Roundup5 min

Weekly FDA Roundup: Amazon gets a warning letter, three Class I food recalls, and a foreign tobacco crackdown, June 20–26, 2026

FDA posted 20 warning letters in a single day, and the biggest name on the list was Amazon itself. Plus three Class I food recalls and a proposed rule targeting foreign tobacco makers.

Read more →
FDA Sent 25 Telehealth Companies the Same Letter on the Same Day. The Violation Was Their Website Copy.
Warning Letter Analysis5 min

FDA Sent 25 Telehealth Companies the Same Letter on the Same Day. The Violation Was Their Website Copy.

On June 8, 2026, FDA sent 25 telehealth companies warning letters over compounded semaglutide and tirzepatide. No inspection took place — FDA read their websites. Two specific marketing claims did most of the damage, and one of them appears in almost every direct-to-consumer health brand's copy.

Read more →
Weekly FDA Roundup: 25 telehealth GLP-1 warning letters, an infant formula botulism recall, and four Class I food recalls, June 13-19, 2026
Weekly Roundup5 min

Weekly FDA Roundup: 25 telehealth GLP-1 warning letters, an infant formula botulism recall, and four Class I food recalls, June 13-19, 2026

FDA posted 25 warning letters to telehealth firms selling compounded GLP-1 drugs in one day, plus four Class I food recalls and an all-lots infant formula recall tied to infant botulism.

Read more →
Weekly FDA Roundup: 22 Class I recalls, an infant formula toxin, and a new sunscreen ingredient, June 6–12, 2026
Weekly Roundup5 min

Weekly FDA Roundup: 22 Class I recalls, an infant formula toxin, and a new sunscreen ingredient, June 6–12, 2026

FDA classified 22 recalls Class I in a single week, nearly half of May's total, led by an infant formula pulled over a heat-stable toxin and a Salmonella wave traced to dry milk powder.

Read more →
One Salmonella-Positive Ingredient, 22 Downstream Class I Recalls: What the California Dairies Cascade Teaches About Supplier Risk
Regulatory Trends5 min

One Salmonella-Positive Ingredient, 22 Downstream Class I Recalls: What the California Dairies Cascade Teaches About Supplier Risk

California Dairies recalled 2.7 million pounds of Salmonella-suspect milk powder in May 2026. Over the next three weeks, four companies that never made milk powder — Griffith Foods, Ghirardelli, PS Seasoning, Legacy Bakehouse — pulled 22 Class I products. Chick-fil-A and Costco were downstream. Here is how an ingredient cascade works, and how to see one coming.

Read more →
Weekly FDA Roundup: a milk powder cascade drives eight Class I recalls, eleven warning letters land in a day, and FDA moves to speed gene therapies, May 30–June 5, 2026
Weekly Roundup6 min

Weekly FDA Roundup: a milk powder cascade drives eight Class I recalls, eleven warning letters land in a day, and FDA moves to speed gene therapies, May 30–June 5, 2026

Eight Class I recalls hit this week, most tracing to one Salmonella-contaminated milk powder or a milk allergen. FDA also posted eleven warning letters in a single day.

Read more →
Weekly FDA Roundup: one tainted dairy ingredient drives 36 Class I recalls, two supplement makers face botulism scares, and Insulet pulls 7 million insulin pods, May 23–29, 2026
Weekly Roundup6 min

Weekly FDA Roundup: one tainted dairy ingredient drives 36 Class I recalls, two supplement makers face botulism scares, and Insulet pulls 7 million insulin pods, May 23–29, 2026

One Salmonella-tainted batch of milk powder from California Dairies drove 36 of the week's 38 Class I recalls, from Ghirardelli cocoa to trail mix, while two supplement makers faced botulism scares.

Read more →
Weekly FDA Roundup: a stent graft tied to three deaths, an 11-letter tobacco sweep, and the first HDV drug, May 16–22, 2026
Weekly Roundup6 min

Weekly FDA Roundup: a stent graft tied to three deaths, an 11-letter tobacco sweep, and the first HDV drug, May 16–22, 2026

FDA logged 59 actions this week, led by a Class I stent graft recall linked to three deaths, four Class I recalls in all, and 11 warning letters to online tobacco sellers.

Read more →
Weekly FDA Roundup: one milk powder triggers a Class I cascade, Raw Farm's E. coli cheddar returns, and FDA reopens BHT, May 9–15, 2026
Weekly Roundup5 min

Weekly FDA Roundup: one milk powder triggers a Class I cascade, Raw Farm's E. coli cheddar returns, and FDA reopens BHT, May 9–15, 2026

A single Salmonella-tainted milk powder from California Dairies drove a wave of Class I recalls across Griffith Foods, Chick-fil-A, and Costco suppliers, while Raw Farm's E. coli cheddar returned.

Read more →
Weekly FDA Roundup: A Class I Pacemaker Recall, a 23-Warning-Letter Day, and the First Flavored E-Cigarette Ever Authorized, May 2–8, 2026
Weekly Roundup6 min

Weekly FDA Roundup: A Class I Pacemaker Recall, a 23-Warning-Letter Day, and the First Flavored E-Cigarette Ever Authorized, May 2–8, 2026

FDA’s most serious action of the week was a battery. A Class I recall hit six Boston Scientific pacemaker families while 23 warning letters landed in a single day and the agency cleared its first-ever flavored e-cigarette.

Read more →
Weekly FDA Roundup: GLP-1 Compounding Hits a Wall, Two Class I Recalls in Diabetes Care, and the First Non-Antipsychotic for Dementia Agitation, April 25 to May 1, 2026
Weekly Roundup7 min

Weekly FDA Roundup: GLP-1 Compounding Hits a Wall, Two Class I Recalls in Diabetes Care, and the First Non-Antipsychotic for Dementia Agitation, April 25 to May 1, 2026

FDA proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Class I recalls for Trividia TRUE METRIX and Insulet Omnipod 5. Auvelity wins first non-antipsychotic dementia agitation approval. Plus three CGMP warning letters.

Read more →
FSVP Warning Letters Hit a Three-Year High: 15 in Four Months and the One Mistake Every Importer Made
Warning Letter Analysis9 min

FSVP Warning Letters Hit a Three-Year High: 15 in Four Months and the One Mistake Every Importer Made

FDA issued 15 FSVP warning letters in the first four months of 2026, a 67% jump over the same period in 2024. Almost every recipient made the same mistake. Here is the pattern and what importers should do this week.

Read more →
Weekly FDA Roundup: A 14-Warning-Letter Day, a New Medicare Coverage Pathway, and the First Gene Therapy for Deafness, April 18–24, 2026
Weekly Roundup8 min

Weekly FDA Roundup: A 14-Warning-Letter Day, a New Medicare Coverage Pathway, and the First Gene Therapy for Deafness, April 18–24, 2026

Fourteen warning letters in a single day, the new RAPID coverage pathway, and the first gene therapy for genetic deafness. What sponsors, compounders, and device kit-makers need to know from April 18–24.

Read more →
The 'Research Use Only' Loophole Just Closed: FDA Hits Seven Peptide Websites in a Single Day
Regulatory Trends6 min

The 'Research Use Only' Loophole Just Closed: FDA Hits Seven Peptide Websites in a Single Day

On April 7, 2026, FDA published seven warning letters against online peptide sellers marketing GLP-1 copycats as 'research use only.' Here's why the disclaimer failed, and what supplement, cosmetic, and wellness brands should learn from the pattern.

Read more →
Weekly FDA Roundup: April 11–17, 2026
Weekly Roundup8 min

Weekly FDA Roundup: April 11–17, 2026

Seven Class I device actions in three days including two tied to the same defective syringe. CDER sweeps four online pharmacies. Purolea Cosmetics Lab cited for using AI to generate compliance docs without Quality Unit review. Plus clinical trial disclosure push and a TRT label-expansion signal.

Read more →
Moringa Salmonella Outbreak 2026: Three Separate Investigations, 169 Illnesses, and a Broken Botanical Supply Chain
Regulatory Trends8 min

Moringa Salmonella Outbreak 2026: Three Separate Investigations, 169 Illnesses, and a Broken Botanical Supply Chain

FDA and CDC have investigated three separate Salmonella outbreaks tied to moringa leaf powder since October 2025. 169 illnesses, 43 hospitalizations, 11 recalls in our database. Here is what every supplement brand with a botanical SKU should do now.

Read more →
Weekly FDA Roundup: April 4–10, 2026
Weekly Roundup5 min

Weekly FDA Roundup: April 4–10, 2026

FDA drops 7 GLP-1 warning letters in one coordinated sweep — the enforcement focus has broadened from compounders and telehealth to raw peptide vendors and eBay arbitrage sellers. Plus three device early alerts, a DSCSA fraud warning at a med spa, and a Wellcovorin NDA withdrawal.

Read more →
FDA Import Alert 66-40: What Happens When Your Drug Supplier Gets Listed
Regulatory Trends6 min

FDA Import Alert 66-40: What Happens When Your Drug Supplier Gets Listed

At least four foreign drug manufacturers were placed on FDA Import Alert 66-40 in Q1 2026. Here is what automatic detention without physical examination means for your supply chain and what to do before your next shipment lands.

Read more →
Weekly FDA Roundup: Oral GLP-1 approved in 50 days, CGMP cluster, and steroid-spiked supplements
Weekly Roundup6 min

Weekly FDA Roundup: Oral GLP-1 approved in 50 days, CGMP cluster, and steroid-spiked supplements

Eli Lilly's Foundayo became the first new molecular entity approved under the FDA's CNPV pilot — 50 days, 294 days ahead of its PDUFA date. Three CGMP warning letters landed the same day, and a supplement recall surfaced undeclared prescription steroids in weight-gain capsules. March 27 to April 3, 2026.

Read more →
Weekly FDA Roundup: Hospital Drug Mix-Up, Natural Dye Delays, and a Cancer "Vaccine" Warning — Week of March 21–28, 2026
Weekly Roundup6 min

Weekly FDA Roundup: Hospital Drug Mix-Up, Natural Dye Delays, and a Cancer "Vaccine" Warning — Week of March 21–28, 2026

Amneal Pharmaceuticals recalls magnesium sulfate pouches after a tranexamic acid mix-up reaches hospitals nationwide. FDA delays beetroot red and spirulina extract approvals indefinitely. ImmunityBio warned over "cancer vaccine" claims for bladder cancer drug ANKTIVA. Plus six warning letters, two Class I device recalls, and two rare pediatric drug approvals.

Read more →
FDA Pharmaceutical Data Integrity Enforcement in 2026: Falsified Records, Destroyed Evidence, and the Import Alert That Follows
Regulatory Trends7 min

FDA Pharmaceutical Data Integrity Enforcement in 2026: Falsified Records, Destroyed Evidence, and the Import Alert That Follows

Five FDA warning letters in Q1 2026 cite deliberate falsification across drug manufacturers, contract labs, and CROs — including records destroyed while investigators were on-site. Here is what it means for US companies sourcing from overseas.

Read more →
Weekly FDA Roundup: Higher-Dose Wegovy Fast-Tracked, Device Recalls Report Injuries and a Death, Week of March 14-20, 2026
Weekly Roundup5 min

Weekly FDA Roundup: Higher-Dose Wegovy Fast-Tracked, Device Recalls Report Injuries and a Death, Week of March 14-20, 2026

Higher-dose Wegovy approved in 54 days via the CNPV program. Two device recalls tied to 22 injuries and one death. Made Fresh Salads pulls 14 cream cheese products for Listeria. Plus 11 warning letters.

Read more →
FDA's Undeclared Prescription Drug Problem: Two Supplement Categories, One Accelerating Enforcement Pattern
Regulatory Trends6 min

FDA's Undeclared Prescription Drug Problem: Two Supplement Categories, One Accelerating Enforcement Pattern

Ten enforcement actions in ten weeks. That is the pace at which FDA has moved against dietary supplements containing undeclared prescription drug ingredients in 2026. Recalls, safety alerts, import holds — the activity spans two distinct product categories, involves a short list of recurring pharmaceutical compounds, and points toward continued escalation.

Read more →
Weekly FDA Enforcement Roundup — March 6–13, 2026
Weekly Roundup6 min

Weekly FDA Enforcement Roundup — March 6–13, 2026

13 warning letters. A new draft guidance on 483 responses. 61 drug approvals pulled. The AEMS launch. And Novo Nordisk in the hot seat over unreported GLP-1 deaths.

Read more →
FDA Inspections in 2026: DOGE Didn't Cut Inspectors — It Cut Everything Around Them
Regulatory Trends5 min

FDA Inspections in 2026: DOGE Didn't Cut Inspectors — It Cut Everything Around Them

FDA is running 36% below pre-pandemic inspection levels. DOGE's 2025 cuts to support staff, lab scientists, and travel logistics made closing that gap harder.

Read more →
FDA's 30 GLP-1 Warning Letters: The Largest Compounding Crackdown in Over a Decade
Regulatory Trends8 min

FDA's 30 GLP-1 Warning Letters: The Largest Compounding Crackdown in Over a Decade

On March 3, 2026, the FDA issued 30 warning letters to telehealth companies selling compounded GLP-1s. Here's what happened, why it matters, and what QA teams should do now.

Read more →
FDA Food Additive Regulations 2026: Red No. 3 Ban, Petroleum Dye Phase-Out, BHA Safety Review, and What Food Brands Must Do Now
Regulatory Trends8 min

FDA Food Additive Regulations 2026: Red No. 3 Ban, Petroleum Dye Phase-Out, BHA Safety Review, and What Food Brands Must Do Now

FDA food additive regulations are seeing their biggest overhaul in decades. Here's the current state of the Red No. 3 ban, petroleum dye phase-out, BHA safety review, and GRAS reform — with deadlines and action items for food brands.

Read more →
30 FDA Warning Letters in a Day: Inside the GLP-1 Compounding Crackdown and the Case That Sent Three Patients to the ER
Warning Letter Analysis8 min

30 FDA Warning Letters in a Day: Inside the GLP-1 Compounding Crackdown and the Case That Sent Three Patients to the ER

The FDA issued 30 warning letters to compounded GLP-1 telehealth companies on March 3, 2026. One documented ER visits from bacterial endotoxin contamination. A deep-dive into the violations—and what every compounding pharmacy must do now.

Read more →
FDA Supplement Regulations 2026: CGMP Violations, 483 Observations, and the New Enforcement Reality
Regulatory Trends5 min

FDA Supplement Regulations 2026: CGMP Violations, 483 Observations, and the New Enforcement Reality

Our analysis of 7,500+ FDA enforcement actions shows supplement enforcement at a decade-high intensity. Here are the CGMP violation patterns, top 483 observations, and substances driving the most regulatory heat in 2026.

Read more →
FDA Recall List 2026: What 1,000 Recalls Reveal About the Biggest Threats to Food Safety
Regulatory Trends7 min

FDA Recall List 2026: What 1,000 Recalls Reveal About the Biggest Threats to Food Safety

Our analysis of 1,000 FDA recall actions reveals the pathogens, allergens, and contaminants driving a 9-year high in food recalls — and the three patterns every food brand needs to understand.

Read more →
MoCRA Compliance in 2026: The Registration Deadline Just Passed — Here's What Comes Next
Regulatory Trends6 min

MoCRA Compliance in 2026: The Registration Deadline Just Passed — Here's What Comes Next

MoCRA biennial registration renewals are underway, with all first renewals due by July 1, 2026. Here's what FDA's expanded authority means for beauty brands, what safety records you must keep, and the new NSF standard that's reshaping compliance.

Read more →
FDA Recall List, March 2026: Undeclared Allergens, Hidden Prescription Drugs, and Plastic Contamination
Weekly Roundup5 min

FDA Recall List, March 2026: Undeclared Allergens, Hidden Prescription Drugs, and Plastic Contamination

The FDA recall list for late February and early March 2026 shows three clear patterns: an allergen labeling wave, prescription drugs in supplement products, and physical contamination at scale.

Read more →
Nobody Monitors the FDA for Your Specific Products. We Built the Thing That Does.
Regulatory Trends4 min

Nobody Monitors the FDA for Your Specific Products. We Built the Thing That Does.

MoCRA renewals, PFAS evaluations, warning letters up 73%. The information is public. The question is whether you know which of YOUR products any of it affects. That cross-reference step is where warning letters live — and nobody automates it. Until now.

Read more →
Weekly FDA Roundup: Compounding Crackdown and Device Safety Alerts — Week of Feb 21–28, 2026
Weekly Roundup6 min

Weekly FDA Roundup: Compounding Crackdown and Device Safety Alerts — Week of Feb 21–28, 2026

55 FDA actions in one week: a landmark framework for ultra-rare genetic disease therapies, a compounding pharmacy warning letter previewing the GLP-1 enforcement surge, four medical device safety alerts from four manufacturers, and two recalls for undeclared prescription drugs in supplements.

Read more →
Weekly FDA Roundup: US-EU Pharma Deal Revoked, Blood Glucose Device Death, and 8 Class I Recalls — Week of Feb 14–21, 2026
Weekly Roundup6 min

Weekly FDA Roundup: US-EU Pharma Deal Revoked, Blood Glucose Device Death, and 8 Class I Recalls — Week of Feb 14–21, 2026

FDA revokes the US-EU pharmaceutical GMP mutual recognition agreement effective March 23, while a blood glucose correction links 114 injuries and one death to an error-code flaw, and five simultaneous Class I recalls sweep a hummus brand.

Read more →
Weekly FDA Roundup: Hormone Therapy Gets a New Label, Botulism Stalks the Supplement Aisle — Week of Feb 7–14, 2026
Weekly Roundup7 min

Weekly FDA Roundup: Hormone Therapy Gets a New Label, Botulism Stalks the Supplement Aisle — Week of Feb 7–14, 2026

FDA removed MHT boxed warnings, approved a first-of-its-kind pancreatic cancer device, launched a BHA reassessment, and fielded 51 recalls — including a 12-SKU Clostridium botulinum sea moss gel cluster.

Read more →
Weekly FDA Roundup: GLP-1 Crackdown, Abbott's Triple Hit, and the Artificial Colors Pivot — Week of Jan 31–Feb 7, 2026
Weekly Roundup7 min

Weekly FDA Roundup: GLP-1 Crackdown, Abbott's Triple Hit, and the Artificial Colors Pivot — Week of Jan 31–Feb 7, 2026

FDA signals the end of the GLP-1 compounding era, Abbott Diabetes Care faces three enforcement actions in 48 hours, and new artificial color policy clears the path for natural alternatives.

Read more →
Weekly FDA Roundup: Flawed Blood Lead Test, FSVP Enforcement Wave, and 22 Recalls — Week of January 26, 2026
Weekly Roundup7 min

Weekly FDA Roundup: Flawed Blood Lead Test, FSVP Enforcement Wave, and 22 Recalls — Week of January 26, 2026

FDA's week of Jan 24–31 brought 35 actions: a warning letter targeting a pediatric blood lead testing device with false positives, four FSVP letters in one day, and 22 recalls dominated by allergen and labeling failures.

Read more →
Weekly FDA Roundup: MAHA Takes Shape in Policy, 28 Recalls, and a Wound Care Alert — Week of Jan 17–24, 2026
Weekly Roundup6 min

Weekly FDA Roundup: MAHA Takes Shape in Policy, 28 Recalls, and a Wound Care Alert — Week of Jan 17–24, 2026

FDA issued a MAHA-driven gluten labeling RFI, reported ImportShield efficiency gains, and posted five warning letters — alongside 28 recalls and a serious wound care device alert from Integra LifeSciences.

Read more →
Weekly FDA Roundup: Pecorino Romano Class I Recall Sweep and CGT Flexibility Shift — Week of Jan 10–17, 2026
Weekly Roundup6 min

Weekly FDA Roundup: Pecorino Romano Class I Recall Sweep and CGT Flexibility Shift — Week of Jan 10–17, 2026

A coordinated 8-product Class I recall from Ambriola Co. swept multiple Pecorino Romano brands; FDA formalized CMC flexibility for cell and gene therapies under Commissioner Makary.

Read more →
Weekly FDA Roundup: Supplement Adulteration, CGMP Cluster, and Nicotine Pouch Crackdown — Week of January 3–10, 2026
Weekly Roundup6 min

Weekly FDA Roundup: Supplement Adulteration, CGMP Cluster, and Nicotine Pouch Crackdown — Week of January 3–10, 2026

FDA opened 2026 with a targeted enforcement week: a dietary supplement recalled for undeclared meloxicam, three CGMP warning letters to OTC manufacturers on the same day, and two tobacco retailers cited for unauthorized nicotine pouches.

Read more →
Weekly FDA Roundup: PFAS in Cosmetics, a Children's Supplement Spiked with an Unapproved Drug, and a Holiday Recall Wave — Week of Dec 27–Jan 3
Weekly Roundup6 min

Weekly FDA Roundup: PFAS in Cosmetics, a Children's Supplement Spiked with an Unapproved Drug, and a Holiday Recall Wave — Week of Dec 27–Jan 3

FDA's MoCRA report finds insufficient safety data for most PFAS in cosmetics; a children's growth supplement contained hidden ibutamoren; seven herbal products recalled in one sweep.

Read more →

What if this analysis was about YOUR products?

Policy Canary monitors the FDA for your specific products — by name, by ingredient, by facility. Start your free trial.

Start Free Trial